- Home
- FCFS vs MDGL Comparison
FCFS vs MDGL Comparison
Compare FCFS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- MDGL
- Stock Information
- Founded
- FCFS 1988
- MDGL 2011
- Country
- FCFS United States
- MDGL United States
- Employees
- FCFS N/A
- MDGL N/A
- Industry
- FCFS Other Specialty Stores
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- MDGL Health Care
- Exchange
- FCFS Nasdaq
- MDGL Nasdaq
- Market Cap
- FCFS 5.9B
- MDGL 6.8B
- IPO Year
- FCFS 1991
- MDGL N/A
- Fundamental
- Price
- FCFS $127.91
- MDGL $275.26
- Analyst Decision
- FCFS Buy
- MDGL Strong Buy
- Analyst Count
- FCFS 3
- MDGL 10
- Target Price
- FCFS $133.50
- MDGL $420.63
- AVG Volume (30 Days)
- FCFS 290.5K
- MDGL 335.5K
- Earning Date
- FCFS 07-24-2025
- MDGL 05-01-2025
- Dividend Yield
- FCFS 1.19%
- MDGL N/A
- EPS Growth
- FCFS 21.73
- MDGL N/A
- EPS
- FCFS 6.25
- MDGL N/A
- Revenue
- FCFS $3,388,567,000.00
- MDGL $317,383,000.00
- Revenue This Year
- FCFS $2.67
- MDGL $285.43
- Revenue Next Year
- FCFS $5.58
- MDGL $63.77
- P/E Ratio
- FCFS $20.47
- MDGL N/A
- Revenue Growth
- FCFS 5.06
- MDGL N/A
- 52 Week Low
- FCFS $100.24
- MDGL $200.63
- 52 Week High
- FCFS $135.57
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- FCFS 50.75
- MDGL 38.56
- Support Level
- FCFS $126.22
- MDGL $265.39
- Resistance Level
- FCFS $128.99
- MDGL $275.54
- Average True Range (ATR)
- FCFS 2.49
- MDGL 11.39
- MACD
- FCFS -0.58
- MDGL -1.08
- Stochastic Oscillator
- FCFS 35.91
- MDGL 24.12
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.